Modified Growth Hormone Releasing Factor (Mod GRF 1-29) and Growth Hormone Releasing Peptide-6 (GHRP-6) are two peptides that researchers believe may support the secretion of growth hormone (GH) from cells in the anterior pituitary gland. The peptides may offer this support through distinct biological pathways. Mod GRF (1-29) is a synthetic peptide derived from Growth Hormone Releasing Hormone (GHRH), an endogenous hormone consisting of 44 amino acids that stimulates GH release. Some studies have indicated that the initial 29 amino acids of GHRH retain their full biological activity.^[1] Modifications to this fragment, resulting in Mod GRF (1-29), are believed to increase its potency and prolong its duration of action, possibly due to better-supported stability against enzymatic degradation.

In contrast, GHRP-6 is a synthetic hexapeptide structurally related to met-enkephalins. Met-enkephalins are endogenous peptides involved in interacting with opioid receptors.^[2] GHRP-6 does not interact with opioid receptors. Rather, GHRP-6 is thought to stimulate GH release by activating ghrelin receptors in the pituitary cells. These receptors are also referred to as growth hormone secretagogue receptors, and thus, GHRP-6 is defined as a growth hormone secretagogue (GHS) peptide. These hypothetical actions of GHRP-6 suggest a mechanism different from that of GHRH analogs like Mod GRF (1-29). Because Mod GRF (1-29) and GHRP-6 are believed to operate through separate receptors and signaling pathways, there is a possibility that their combined implications as a blend might produce synergistic action on GH secretion in experimental settings.